Additionally, the activity, efficacy, and safety of anti-PD-1 drugs are currently being evaluated in the neoadjuvant and adjuvant settings for patients with advanced CSCC (Table 1 and Table 2). The gene discussed is PDCD1; the disease is skin squamous cell carcinoma.